Innate Pharma hosts event on IPH4502 Phase 1 data and development outlook
IPHA•Innate Pharma will host an in-person and virtual event in London on November 18, 2026, to review Phase 1 dose-escalation results for its Nectin-4 ADC IPH4502 and discuss the drug’s development outlook.
1. Event details
Innate Pharma will host the event at 11 a.m. ET/4 p.m. GMT on November 18, 2026. Presentations will review safety, pharmacokinetics and antitumor activity from IPH4502’s Phase 1 dose-escalation results.
2. Clinical perspective
Yohann Loriot will provide a clinical perspective on urothelial cancer, while management will discuss the drug’s development outlook.
